These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15919767)

  • 1. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind".
    Goodwin JT; Clark DE
    J Pharmacol Exp Ther; 2005 Nov; 315(2):477-83. PubMed ID: 15919767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the blood-brain barrier in CNS drug discovery.
    Jeffrey P; Summerfield S
    Neurobiol Dis; 2010 Jan; 37(1):33-7. PubMed ID: 19664709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current in vitro and in silico models of blood-brain barrier penetration: a practical view.
    Vastag M; Keseru GM
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):115-24. PubMed ID: 19152220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of CNS activity of compound libraries using substructure analysis.
    Engkvist O; Wrede P; Rester U
    J Chem Inf Comput Sci; 2003; 43(1):155-60. PubMed ID: 12546548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery and in vitro models of the blood-brain barrier.
    Cucullo L; Aumayr B; Rapp E; Janigro D
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):89-99. PubMed ID: 15679176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
    Adenot M; Perriere N; Scherrmann JM; Lahana R
    Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
    Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-brain barrier permeability considerations for CNS-targeted compound library design.
    Hitchcock SA
    Curr Opin Chem Biol; 2008 Jun; 12(3):318-23. PubMed ID: 18435937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of blood brain barrier permeability: an Artificial Neural Network model.
    Garg P; Verma J
    J Chem Inf Model; 2006; 46(1):289-97. PubMed ID: 16426064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constructing optimum blood brain barrier QSAR models using a combination of 4D-molecular similarity measures and cluster analysis.
    Pan D; Iyer M; Liu J; Li Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2004; 44(6):2083-98. PubMed ID: 15554679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple predictive model for blood-brain barrier penetration.
    Fu XC; Song ZF; Fu CY; Liang WQ
    Pharmazie; 2005 May; 60(5):354-8. PubMed ID: 15918585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a pharmacophore-based QSAR model for the prediction of CNS activity.
    Gozalbes R; Barbosa F; Nicolaï E; Horvath D; Froloff N
    ChemMedChem; 2009 Feb; 4(2):204-9. PubMed ID: 19097128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges for blood-brain barrier (BBB) screening.
    Jeffrey P; Summerfield SG
    Xenobiotica; 2007; 37(10-11):1135-51. PubMed ID: 17968740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of physiologically based absorption models in drug discovery and development.
    Parrott N; Lave T
    Mol Pharm; 2008; 5(5):760-75. PubMed ID: 18547054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A physiologically based modeling strategy during preclinical CNS drug development.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Mol Pharm; 2014 Mar; 11(3):836-48. PubMed ID: 24446829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.